[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report].

Hypolipemic agents, both statins and fibrates, may cause a spectrum of side-effects, including the transient increase in creatine phosphokinase (CPK) activity. Muscle injury may present as common myalgia, non-specific myositis with normal CPK levels, myopathy and in the most serious cases, as rhabdomyolysis. Muscle damage is much more probably in patients with concomittant kidney and liver diseases, hypothyroidism, and serious infections or after some injuries or a heavy physical effort. On the other hand, one of the most common causes of secondary hypercholesterolemia and myopathy is hypothyroidism. This condition, which may enhance the risk of muscle damage in the course of hypolipemic treatment, may sometimes present with an atypical clinical presentation, making its diagnosis challenging. In this article, we present the case of a 50-year-old male physical worker presented with marked dyslipidemia, in whom myopathy was diagnosed during therapy with hypolipemic agents. Cessation of the treatment resulted in the only moderate reduction of CPK activity. Only just the introduction of thyroid hormone supplementation led to regression of symptoms and normalization of abnormalities found in laboratory examinations including remarkable improvement in lipid profile. After several months of observation we consider that hypolipemic treatment probably revealed previously occult autoimmune thyroid disease in this patient.

[1]  B. Miskie,et al.  Genetic determinants of statin intolerance , 2007, Lipids in Health and Disease.

[2]  Richard Platt,et al.  Risk factors for statin‐associated rhabdomyolysis , 2007, Pharmacoepidemiology and drug safety.

[3]  Y. Chatzizisis,et al.  The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. , 2007, European journal of internal medicine.

[4]  Y. Matsushima,et al.  HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. , 2006, Endocrine journal.

[5]  Z. Odabaşı,et al.  Early diagnosis and treatment reverse clinical features in Hoffmann's syndrome due to hypothyroid myophaty: a case report. , 2005, Acta neurologica Belgica.

[6]  J. Bleecker How to approach the patient with muscular symptoms in the general neurological practice , 2005 .

[7]  M. Mastropasqua,et al.  Hoffman’s Syndrome: Muscle Stiffness, Pseudohypertrophy and Hypothyroidism , 2003, Hormone Research in Paediatrics.

[8]  J. Finsterer Fibrat-/Statin-Myopathie , 2003, Der Nervenarzt.

[9]  B. Jacotot,et al.  [Muscular toxicity of antilipemic agents revealed during the course of hypothyroidism]. , 2003, Presse medicale.

[10]  Allen Shek,et al.  Statin—Fibrate Combination Therapy , 2001, The Annals of pharmacotherapy.

[11]  C. K. Liu,et al.  Hypothyroid myopathy-pathological and ultrastructural study. , 2000, The Kaohsiung journal of medical sciences.

[12]  C. C. Huang,et al.  [Hypothyroid myopathy: a case report]. , 1999, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[13]  I. Beyer,et al.  Serum creatine kinase levels in overt and subclinical hypothyroidism. , 1998, Thyroid : official journal of the American Thyroid Association.

[14]  C. Glueck,et al.  Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[15]  L. Bazzichi,et al.  Polymyositis-like syndrome in hypothyroidism: report of two cases. , 1994, Thyroidology.

[16]  I. Klein,et al.  Hypothyroidism presenting as muscle stiffness and pseudohypertrophy: Hoffmann's syndrome. , 1981, The American journal of medicine.